Promising Startups 2022
2022 VC Survey
Beware of the cyber Frankenstein: Figuring out Thoma Bravo’s next move
Facing the music: Streaming saved music, but squashed musicians
Startup reality check: Founders and VCs face accountability wake-up call
Green Apple: How Apple turned the Watch into a product with zero emissions
Cisco pulled out of SentinelOne acquisition after due diligence revealed ARR inaccuracies
Palo Alto Networks in negotiations to acquire Talon Cyber Security in $600 million deal
CrowdStrike acquiring cyber startup Bionic for $350 million
Israel’s Playermaker approved by FIFA to track player performance in official games
Palo Alto Networks Founder: "Only a few dominant players will survive the cyber consolidation"
20 stories about Teva
$300 million Teva bet: Will Norway's wealth fund and ION regret investing in the pharma giant?
ION, which manages investments for the Norwegian wealth fund, began a buying spree of Teva shares at the beginning of the year
Closure of another criminal case will help Teva's new CEO to focus on return to growth
The pharmaceutical company has reached a compromise after being suspected of price-fixing with other generic drug manufacturers in the US. In the first four years, it will pay $22.5 million and in 2028 - $135 million. In addition, the company will donate two drugs worth $50 million to humanitarian organizations
Teva profit plummets, stock slides
Teva plans to unveil a new strategy next week which CEO Francis said would "build on Teva's strong foundations, key strengths, and sets the stage for long-term growth"
Schultz kept Teva away from the abyss, but couldn't find a runway to growth
Kare Schultz, who served as CEO of the pharmaceutical company for the past five years, has left the company a year early after amassing a salary of more than $100 million. His replacement, Richard Francis, is taking over with less debt and less legal issues, but with the big challenge of creating new growth engines
Teva names Richard Francis as new CEO after Kåre Schultz departure
Francis is the former CEO of Sandoz and was also a senior executive at Biogen for 13 years
Why are investors so pleased about Teva's $4.35 billion opioid settlement?
The settlement removes the cloud of uncertainty that hovered over Teva, which on the one hand prevented investors from placing trust in its stock, while on the other hand also prevented Teva management from making substantial moves
Teva reaches $4.35 billion settlement in U.S. opioid lawsuits, shares surge
Sophie Shulman and Reuters
Teva is set to pay state and local governments up to $3.7 billion in cash over 13 years plus a contribution of $1.2 billion worth of the opioid overdose reversal drug naloxone
Ichilov Hospital and Sanara Ventures to join forces to promote innovation in neurology
The investment platform will invest in the hospital’s innovative technologies, giving it the opportunity to identify early-stage startups in the fields of neurology, digital health
Holocaust memorial event March of the Living goes virtual because of Covid-19
In honor of Holocaust Memorial Day, the annual march to former Auschwitz concentration camp to commemorate survivors will be hosted in an online format, feature U.S. coronavirus czar Dr. Anthony Fauci, Pfizer CEO
Israeli startup MyHomeDoc receives FDA approval for smartphone-based telemedicine
The MyHomeDoc device is capable of testing the most common vital signs for primary medical care and all from a smartphone
People learn more about a workplace in the hallways than in interviews
During a year of working remotely, many companies were forced to improve their recruitment process through apps, video interviews, and built-in digital questionnaires, which have forever changed the way companies sort through candidates
With the cloud blocking its horizon, Check Point is facing its moment of truth
Under Gil Shwed's conservative leadership, the Israeli cybersecurity giant didn't capitalize fast enough on the cloud, leaving it to face some hard decisions
Teva in talks with Covid-19 vaccine manufacturers to co-produce shots
Reuters and CTech
"We are positive towards contributing by manufacturing some of those vaccines that either have been approved or are just about to be approved," said CEO
Teva beats analysts predictions with increased revenues from growth drivers
The Israeli pharmaceutical company concluded the quarter with $4.5 billion in revenues, bringing it to a total of $16.6 billion for 2020
These are the key ingredients of Israel's rapid Covid-19 vaccine rollout recipe
Two weeks into its vaccination drive, Israel has reached nearly 15% of the population by paying premium prices, relying on universal healthcare, and minimizing waste
Israel-based IMedis receives CE approval for radiology scans in EU
The company operates as part of Teva and Philips’ investment platform, Sanara Ventures
Pfizer, AstraZeneca, Merck, and Teva win tender for new Israeli Innovation Lab
The lab, which is set to research digital health and computational biology, has a government budget of $9.9 million
Who is planning the biggest IPO in Israeli history and which company raised $32 million?
CTech Daily Roundup: Israeli cybersecurity company ReSec raises $4 million in series A
Teva holds Bio-Mix competition to inspire innovative health solutions
Winning prize goes to student at Tel Aviv University who developed a way to digitally treat hearing problems
Who is going to stop FANMAG stocks and what is holding back Teva?
CTech Daily Roundup: Indian Ambassador says strategic partnership with Israel is crucial to coping with fundamental disruptions.
UI & UX by